Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571254 | 0.91 | NR3C1 (0.64) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL8242650 | 0.91 | NR3C1 (0.64) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4978346 | 0.87 | NR3C1 (0.61) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4978357 | 0.87 | NR3C1 (0.61) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL27046934 | 0.87 | CYP19A1 (0.63) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL17775785 | 0.87 | CYP19A1 (0.63) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL29534861 | 0.86 | NR3C1 (0.66) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL10390166 | 0.86 | NR3C1 (0.66) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL18351260 | 0.84 | NR3C1 (0.78) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL7189243 | 0.84 | NR3C1 (0.47) | NR3C1CYP19A1ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | claimed |
| US-7417140-B2 | 17 beta -Hydroxy-7 alpha -(2'-hydroperoxy-2'-methoxyacetyl)pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone chemical intermediate useful to prepare eplerenone a hypotensive agent, useful for treating congestive heart failure | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1487859-B1 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN CO LLC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070117780-A1 | 17 beta -Hydroxy-7 alpha -(2'-hydroperoxy-2'-methoxyacetyl)pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone chemical intermediate useful to prepare eplerenone a hypotensive agent, useful for treating congestive heart failure | PHARMACIA & UPJOHN COMPANY | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117780-A1 | 17 beta -Hydroxy-7 alpha -(2'-hydroperoxy-2'-methoxyacetyl)pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone chemical intermediate useful to prepare eplerenone a hypotensive agent, useful for treating congestive heart failure | HSD17B7, HSD11B1, HSD11B2 | NR3C1 65/4885CYP19A1 150/4885AR 123/4885 |
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | NR3C2, HSD3B2, HSD11B2 | NR3C1 19/4885CYP19A1 135/4885AR 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.